Method to supplement human immune system in suppressing hsv symptoms

A method of administering orally a therapeutically effective pharmaceutical formulation of allicin in a pharmaceutical dosage form to a patient with a herpes simplex viral infection, the therapeutically effective pharmaceutical formulation of allicin for increasing a human immune system activity in the patient during a reactivation of a herpes simplex virus causing a prodromal phase of the herpes simplex virus outbreak in the patient, the increasing of the human immune system activity in the patient for suppressing a herpes simplex viral symptom in the patient, the method comprising the steps of:

• administering orally a first therapeutically effective pharmaceutical formulation of the allicin with a dose of the allicin in an amount of between about 7,200 micrograms to about 12,000 micrograms in the pharmaceutical dosage form during onset of the prodromal phase of the herpes simplex virus outbreak in the patient;
• administering orally a second pharmaceutical formulation of the allicin with the dose of the allicin in the amount of between about 3,000 micrograms to about 4,800 micrograms in the pharmaceutical dosage form during the prodromal phase of the herpes simplex virus outbreak in the patient;
• administering orally a third pharmaceutical formulation of the allicin with the dose of the allicin in the amount of between about 3,000 micrograms to about 4,800 micrograms in the pharmaceutical dosage form during the prodromal phase of the herpes simplex virus outbreak in the patient;
• administering orally a fourth pharmaceutical formulation of the allicin with the dose of the allicin in the amount of between about 3,000 micrograms to about 4,800 micrograms in the pharmaceutical dosage form during the prodromal phase of the outbreak in the patient;
• administering orally a fifth oral dose in the amount of between about 3,000 micrograms to about 4,800 micrograms in the pharmaceutical dosage form during the prodromal phase of the herpes simplex virus outbreak in the patient;
• administering orally a sixth pharmaceutical formulation of the allicin with the dose of the allicin in the amount of between about 3,000 micrograms to about 4,800 micrograms in the pharmaceutical dosage form during the prodromal phase of the herpes simplex virus outbreak in the patient;
• administering orally a seventh pharmaceutical formulation of the allicin with the dose of the allicin in the amount of between about 3,000 micrograms to about 4,800 micrograms in the pharmaceutical dosage form during the prodromal phase of the herpes simplex virus outbreak in the patient;
• administering orally an eighth pharmaceutical formulation of the allicin with the dose of the allicin in the amount of between about 3,000 micrograms to about 4,800 micrograms in the pharmaceutical dosage form during the prodromal phase of the herpes simplex virus outbreak in the patient;
• administering orally a ninth pharmaceutical formulation of the allicin with the dose of the allicin in the amount of between about 3,000 micrograms to about 4,800 micrograms in the pharmaceutical dosage form during the prodromal phase of the herpes simplex virus outbreak in the patient;
• administering orally a tenth pharmaceutical formulation of the allicin with the dose of the allicin in the amount of between about 3,000 micrograms to about 4,800 micrograms in the pharmaceutical dosage form during the prodromal phase of the herpes simplex virus outbreak in the patient;
• and
• suppressing the herpes simplex virus symptom in the patient during the prodromal phase of the herpes simplex virus outbreak in the patient, and
• wherein the administering orally of the therapeutically effective pharmaceutical formulation of allicin in the pharmaceutical dosage form to the patient occurs over a time interval selected from the group consisting of an hourly time interval, and a daily time interval, and a combination thereof.